UBS Group’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.81M | Buy |
|
|||||
|
2025
Q1 | $3.2M | Buy |
|
|||||
|
2024
Q4 | $2.9M | Buy |
|
|||||
|
2024
Q3 | $1.15M | Sell |
|
|||||
|
2024
Q2 | $3.27M | Buy |
|
|||||
|
2024
Q1 | $2.42M | Buy |
|
|||||
|
2023
Q4 | $1.36M | Buy |
|
|||||
|
2023
Q3 | $414K | Sell |
|
|||||
|
2023
Q2 | $582K | Buy |
|
|||||
|
2023
Q1 | $86.9K | Sell |
|
|||||
|
2022
Q4 | $111K | Buy |
|
|||||
|
2022
Q3 | $31K | Sell |
|
|||||
|
2022
Q2 | $60K | Sell |
|
|||||
|
2022
Q1 | $3.52M | Buy |
|
|||||
|
2021
Q4 | $4.15M | Sell |
|
|||||
|
2021
Q3 | $3.75M | Buy |
|
|||||
|
2021
Q2 | $1.26M | Buy |
|
|||||
|
2021
Q1 | $573K | Sell |
|
|||||
|
2020
Q4 | $519K | Buy |
|
|||||
|
2020
Q3 | $460K | Sell |
|
|||||
|
2020
Q2 | $848K | Buy |
|
|||||
|
2020
Q1 | $315K | Sell |
|
|||||
|
2019
Q4 | $1.36M | Sell |
|
|||||
|
2019
Q3 | $4.97M | Buy |
|
|||||
|
2019
Q2 | $1.28M | Sell |
|
|||||
|
2019
Q1 | $4.44M | Sell |
|
|||||
|
2018
Q4 | $6.3M | Buy |
|
|||||
|
2018
Q3 | $10.6M | Buy |
|
|||||
|
2018
Q2 | $4.06M | Sell |
|
|||||
|
2018
Q1 | $10.3M | Buy |
|
|||||
|
2017
Q4 | $1.5M | Sell |
|
|||||
|
2017
Q3 | $3.7M | Sell |
|
|||||
|
2017
Q2 | $4.74M | Buy |
|
|||||
|
2017
Q1 | $1.99M | Sell |
|
|||||
|
2016
Q4 | $5.74M | Buy |
|
|||||
|
2016
Q3 | $2.92M | Sell |
|
|||||
|
2016
Q2 | $5.57M | Buy |
|
|||||
|
2016
Q1 | $1.3M | Sell |
|
|||||
|
2015
Q4 | $7.25M | Buy |
|
|||||
|
2015
Q3 | $2.79M | Buy |
|
|||||
|
2015
Q2 | $2.53M | Buy |
|
|||||
|
2015
Q1 | $1.78M | Buy |
|
|||||
|
2014
Q4 | $448K | Buy |
|